We are live on ! Find out more
DB

DCVC Bio Portfolio holdings

AUM $313K
This Fund
S&P 500
This Quarter Est. Return
-28.64%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$104M
AUM Growth
–
Cap. Flow
+$111M
Cap. Flow %
106.12%
Top 10 Hldgs %
100%
Holding
1
New
1
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
ABCL icon
AbCellera Biologics
ABCL
+$111M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABCL icon
1
AbCellera Biologics
ABCL
$1.82B
$104M 100%
+7,305,761
New +$111M

Similar funds

FRCMI
First Round Capital Management III Philadelphia, Pennsylvania $418K AUM
ICMH
Integrity Capital Management (HK) Central, Hong Kong $64K AUM
SP
Sage Partners Hong Kong $23K AUM
MGPI
Maveron General Partner IV Seattle, Washington $8K AUM
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
ACMV
August Capital Management VI Palo Alto, California $1.39M AUM
NAM
Newfleet Asset Management Hartford, Connecticut $2.05M AUM 27.28% 1-Year Est. Return
AP
Atlas Principals Charlotte, North Carolina $2.19M AUM 56.71% 1-Year Est. Return

DCVC Bio's Q4 2021 Portfolio in Review

Q4 2021 is the first quarter with a 13F filing on record for DCVC Bio, which disclosed 1 position worth $104M. Its ten largest holdings account for 100% of the portfolio.

Its largest position is AbCellera Biologics: 7,305,761 shares worth $104M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • DCVC Bio's largest Q4 2021 buy was AbCellera Biologics: 7,305,761 shares worth $104M.
  • DCVC Bio's ten largest holdings make up 100% of its $104M portfolio in Q4 2021.
  • DCVC Bio disclosed 1 position in Q4 2021, its first 13F filing on record.

Based on DCVC Bio's 13F filing for Q4 2021, filed 14 Feb 2022.